Project Grant HT94252410215
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$2.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The Johns Hopkins University received a $2,455,671.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an AAV-based gene therapy for amyotrophic lateral sclerosis (ALS). The award, effective June 1, 2024 through May 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research and advance therapeutic solutions for this neurological disorder. The federal grant funding supports the university's...
The Johns Hopkins University was awarded a $1,623,356 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2026 to develop CHMP7 antisense oligonucleotide (ASO) therapy to repair nuclear pore and TDP43 dysfunction in sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports basic, applied, and...
This $798,272 federal Project Grant was awarded by the Defense Health Agency on March 15, 2025 under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by The Johns Hopkins University to test the use of Wnt inhibitors as a potential therapeutic approach to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The project aims to explore innovative medical solutions for this challenging neurological disease, with a focus on...
The Department of the Army Medical Command awarded The Johns Hopkins University a $982,500 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Targeting M6A Dysregulation as a Novel Therapeutic Strategy for C9ORF72-ALS". The award period is May 1, 2024 to April 30, 2026. This research aims to develop new treatments for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), with a focus on the C9ORF72 genetic...
This $1,137,301 federal Project Grant awarded by the Defense Health Agency on July 1, 2024 supports The Johns Hopkins University's work on "MULTI-MODAL, REMOTE TRACKING OF ALS PROGRESSION USING NOVEL DIGITAL BIOMARKERS" through June 30, 2026. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The project aims to develop...
The U.S. Department of the Army Medical Command has awarded a $931,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University to develop a RIPK2 inhibitor for the treatment of ALS. The project will be conducted from July 1, 2025 through June 30, 2027. As a leading research university with extensive experience supporting critical medical research initiatives for federal agencies, Johns Hopkins will leverage its expertise in...
This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $307,511.00 to the University of Maryland, Baltimore (UMB) to facilitate the extinction of fear with psilocybin. The performance period runs from Feb 1, 2024 to Jan 31, 2026. The Military Medical Research and Development program supports a range of biomedical research aimed at improving the health and care of military service members, veterans, and...
The Johns Hopkins University was awarded an $818,750 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support research into RNA-based modulation of TDP-43 mislocalization in ALS/FTD with uridine analogs from September 15, 2022 to September 14, 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
The Department of the Army Medical Command awarded The Johns Hopkins University a $814,065 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, with a performance period from December 1, 2024 to November 30, 2026, will fund research on "MECHANISMS OF IRISIN-INDUCED COGNITIVE BENEFIT IN PD." As a leading academic research institution, The Johns Hopkins University will leverage its expertise in biomedical research,...
The Johns Hopkins University was awarded a $982,500 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund preclinical studies of Bryostatin-1 to promote remyelination and repair in multiple sclerosis from July 15, 2021 to July 14, 2024. Through this funding, The Johns Hopkins University will investigate medical solutions for the battlefield by conducting applied and advanced biomedical research into...